To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Plain-language summary
This trial is testing Belinostat and Pralatrexate either alone or in combination with CHOP chemotherapy for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment, as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 11 locations in the United States.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Belinostat Injection (DRUG): Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle | Pralatrexate Injection (DRUG): Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle | CHOP (DRUG): CHOP is the comparator arm | COP (DRUG): COP is given in combination with Pralatrexate
Belinostat Injection, Pralatrexate Injection, CHOP, COP
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details